Waltham, MA – June 18, 2015 - Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that a complex percutaneous coronary intervention (PCI) was broadcast live to attendees of the 2015 Complex Cardiovascular Catheter Therapeutics Conference in Orlando, Florida. Interventional cardiologists from around the world watched Arif Al Nooryani, MD, perform the triple-vessel disease case robotically in real-time by deploying bioresorbable stents, wiring the lesion and placing the stents using the CorPath System.
During the procedure, Dr. Al Nooryani, Chief Executive Officer and Head of the Cardiology Department at Al Qassimi Hospital, Sharjah, United Arab Emirates, sat in the CorPath System's radiation-shielded interventional cockpit and did not need to wear a lead apron as he advanced the guidewires, balloons, and stents without being exposed to the hazards of x-ray radiation.
“This case showed how robotic technology is effective in the treatment of patients with complex disease, while protecting me from the occupational hazards of the cath lab,” said Dr. Al Nooryani. “The enhanced visualization and precision provided by the CorPath System enabled me to place the bioresorbable vascular scaffold with optimal results for my patient.”
Developed by Corindus Vascular Robotics, the CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to coronary interventional procedures. The CorPath System is currently indicated in the US only for percutaneous coronary interventions.
For more information about the CorPath System, visit www.corindus.com.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements:
